In addition, EA may improve chronic neuropathic pain and depression‐like behaviors by modulating the CREB‐5‐hydroxytryptamine (5‐HT)/BDNF signaling pathway (Cong et al., 2021). This evidence concerns the gene CREB1 and major depressive disorder.